Windtree Therapeutics (WINT) News Today $1.64 -0.06 (-3.53%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.66 +0.03 (+1.52%) As of 03/27/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Evofem announces license and supply agreement with Windtree TherapeuticsMarch 27 at 9:38 AM | markets.businessinsider.comEvofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree TherapeuticsMarch 26 at 8:47 AM | prnewswire.comWindtree Therapeutics Regains Compliance with Nasdaq Listing RulesMarch 24, 2025 | globenewswire.comWindtree Therapeutics (NASDAQ:WINT) Stock, Insider Trading ActivityMarch 21, 2025 | benzinga.comWindtree to become sourcing partner for Evofem BiosciencesMarch 21, 2025 | markets.businessinsider.comWindtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI®March 21, 2025 | msn.comAnother Day, Another Biotech Ripping Before The BellMarch 20, 2025 | msn.comWindtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved ProductMarch 20, 2025 | globenewswire.comWindtree Therapeutics (NASDAQ:WINT) and AIM ImmunoTech (NYSE:AIM) Head to Head ComparisonMarch 20, 2025 | americanbankingnews.comWINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating CoverageMarch 4, 2025 | msn.comWindtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart FailureMarch 4, 2025 | markets.businessinsider.comWindtree Therapeutics announces notice of allowance from USPTO for istaroximeMarch 4, 2025 | markets.businessinsider.comWindtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia TreatmentMarch 2, 2025 | msn.comWindtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for IndiaFebruary 27, 2025 | markets.businessinsider.comWindtree Therapeutics files patent in India for cardiac arrythmia therapyFebruary 27, 2025 | markets.businessinsider.comWindtree Therapeutics Inc trading halted, news pendingFebruary 20, 2025 | markets.businessinsider.comWindtree Therapeutics board approves 1-for-50 reverse stock splitFebruary 19, 2025 | markets.businessinsider.comWindtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq ComplianceFebruary 18, 2025 | msn.comWindtree Therapeutics, Inc. Announces Reverse Stock SplitFebruary 18, 2025 | markets.businessinsider.comWindtree Therapeutics files to sell 40M shares of common stock for holdersFebruary 14, 2025 | markets.businessinsider.comWindtree Therapeutics announces istaroxime presentation on Phase 2b studyFebruary 13, 2025 | markets.businessinsider.comWindtree reports positive Phase 2b study on heart failure therapyFebruary 13, 2025 | msn.comWindtree Therapeutics enacts reverse stock split, expands equity planFebruary 4, 2025 | msn.comWINT stock touches 52-week low at $0.13 amid steep annual declineJanuary 29, 2025 | msn.comWindtree Therapeutics adjusts Series C Preferred Stock termsJanuary 27, 2025 | msn.comWINT stock touches 52-week low at $0.21 amid sharp annual declineJanuary 21, 2025 | msn.comWindtree Therapeutics Secures Patent in Japan for Cancer Treatment PlatformJanuary 19, 2025 | msn.comWindtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth StrategyJanuary 17, 2025 | msn.comWindtree announces issuance of patent in Japan for oncology pipelineJanuary 16, 2025 | markets.businessinsider.comWarrington’s Windtree Therapeutics Eyes Acquisitions to Stay AfloatJanuary 15, 2025 | msn.comWindtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology PipelineJanuary 15, 2025 | markets.businessinsider.comWindtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology PipelineJanuary 15, 2025 | globenewswire.comWindtree Announces the Addition of Leanne Kelly to Its Board of DirectorsJanuary 13, 2025 | globenewswire.comWindtree Therapeutics Highlights Istaroxime’s Promise for Cardiogenic ShockDecember 19, 2024 | msn.comWindtree Therapeutics announces presentation highlighting istaroximeDecember 17, 2024 | markets.businessinsider.comWindtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceDecember 16, 2024 | finance.yahoo.comWindtree Therapeutics announces new istaroxime patent filingDecember 11, 2024 | markets.businessinsider.comWindtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaDecember 9, 2024 | globenewswire.comH.C. Wainwright Sticks to Their Hold Rating for Windtree Therapeutics (WINT)December 5, 2024 | markets.businessinsider.comWindtree Therapeutics announces partnership with New Growth AdvisorsDecember 5, 2024 | markets.businessinsider.comWindtree Therapeutics Engages New Growth Advisors to Explore Strategic OpportunitiesDecember 5, 2024 | msn.comWindtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionDecember 4, 2024 | globenewswire.comWindtree Therapeutics Reports Q3 Results and Highlights Key Business AchievementsDecember 1, 2024 | msn.comWindtree Therapeutics Reports Q3 2024 Financial ResultsNovember 28, 2024 | markets.businessinsider.comWindtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNovember 28, 2024 | markets.businessinsider.comWindtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNovember 27, 2024 | globenewswire.comLeadership Transition at Windtree Therapeutics: Fraser Retires, Latkin Takes HelmNovember 16, 2024 | msn.comWindtree Announces Leadership Transition Plan With Industry VeteransNovember 14, 2024 | markets.businessinsider.comWINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position ExpandsNovember 13, 2024 | finance.yahoo.comWindtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure TreatmentNovember 6, 2024 | msn.com Remove Ads Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address WINT Media Mentions By Week WINT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. WINT News Sentiment▼0.480.78▲Average Medical News Sentiment WINT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. WINT Articles This Week▼82▲WINT Articles Average Week Remove Ads Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNOA News Today ENSC News Today ONVO News Today PWUP News Today KZIA News Today CPHI News Today CMND News Today ADIL News Today APM News Today CELZ News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:WINT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy WINT Stock Free WINT Stock Alerts